Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Solid Tumors Using 124I-Humanized 3F8
NCT02307630Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2014
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of 124I-humanized 3F8 in melanoma, neuroblastoma, sarcoma and 4 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Pharmacokinetics of 124I-hu3F8 at 96 hours. Started Nov 2014; status: active, not recruiting.
02
Drugs
124I-humanized 3F8
03
Conditions
melanomaneuroblastomasarcomasmall cell lung cancer (SCLC)medulloblastoma
Beyond the preview
Go deeper on NCT02307630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307630.